Protective effect of procaine hydrochloride on cisplatin-induced alterations in rat kidney

Carla Fenoglio, Clodomiro Andrea Boicelli, Massimo Ottone, Concetta Addario, Patrizia Chiari, Maurizio Viale

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Efforts have been made to reduce the undesirable side effects of cisplatin, mainly nephro- and neurotoxicity, but their reduction is usually accompanied by a concomitant inhibition of antitumor activity. The local anesthetic procaine hydrochloride (P.HCl) improves the therapeutic index of cisplatin not only by the reduction of its nephro- and hemotoxicity, but also by an increase of its antitumor activity. We therefore investigated the effects of a combined treatment of cisplatin and P.HCl on rat kidneys and compared this to kidneys from rats treated with a toxic dose of cisplatin or P.HCl alone. Treatment with a saline solution was used as control. Dehydrogenase activities [succinate dehydrogenase (SDH) and NADPH diaphorase reaction demonstrating nitric oxide synthase (NOS/NADPHd)] and phosphatase activities [K+ p-nitrophenyl phosphatase (K+ pNPPase), alkaline phosphatase (AlPase) and acid phosphatase (AcPase)] were studied on cryostatic sections of kidneys from controls and treated rats. Evidence of heavy morphological damage and altered AlPase and AcPase activities induced by cisplatin were observed in the S3 segment of the proximal tubules. In addition, SDH and K+ pNPPase activities showed some changes in the distal tubule cells. The NOS/NADPHd activity in macula densa was drastically reduced. Combined treatment of cisplatin and P.HCl greatly attenuated morphological alterations of the rat kidney and reduced the changes in enzyme activities, except for NOS/NADPHd activity, compared to the cisplatin-treated group of animals. The study indicates that, in cisplatin-induced nephrotoxicity, a significant role is played by enzyme activities, in particular K+ pNPPase and NOS/NADPHd, and that P.HCl can mitigate the nephrotoxicity of cisplatin, possibly by influencing some enzyme activities involved in important renal metabolic pathways.

Original languageEnglish
Pages (from-to)1043-1054
Number of pages12
JournalAnti-Cancer Drugs
Volume13
Issue number10
DOIs
Publication statusPublished - Nov 2002

Fingerprint

Procaine
Cisplatin
Kidney
4-Nitrophenylphosphatase
Succinate Dehydrogenase
Acid Phosphatase
Alkaline Phosphatase
Enzymes
NADPH Dehydrogenase
Poisons
Metabolic Networks and Pathways
Local Anesthetics
Phosphoric Monoester Hydrolases
Sodium Chloride
Nitric Oxide Synthase
Oxidoreductases

Keywords

  • Cisplatin
  • Enzymes
  • Nephrotoxicity
  • Procaine

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Cite this

Protective effect of procaine hydrochloride on cisplatin-induced alterations in rat kidney. / Fenoglio, Carla; Boicelli, Clodomiro Andrea; Ottone, Massimo; Addario, Concetta; Chiari, Patrizia; Viale, Maurizio.

In: Anti-Cancer Drugs, Vol. 13, No. 10, 11.2002, p. 1043-1054.

Research output: Contribution to journalArticle

Fenoglio, Carla ; Boicelli, Clodomiro Andrea ; Ottone, Massimo ; Addario, Concetta ; Chiari, Patrizia ; Viale, Maurizio. / Protective effect of procaine hydrochloride on cisplatin-induced alterations in rat kidney. In: Anti-Cancer Drugs. 2002 ; Vol. 13, No. 10. pp. 1043-1054.
@article{604132e6187542aba49c69ef4f9d4a83,
title = "Protective effect of procaine hydrochloride on cisplatin-induced alterations in rat kidney",
abstract = "Efforts have been made to reduce the undesirable side effects of cisplatin, mainly nephro- and neurotoxicity, but their reduction is usually accompanied by a concomitant inhibition of antitumor activity. The local anesthetic procaine hydrochloride (P.HCl) improves the therapeutic index of cisplatin not only by the reduction of its nephro- and hemotoxicity, but also by an increase of its antitumor activity. We therefore investigated the effects of a combined treatment of cisplatin and P.HCl on rat kidneys and compared this to kidneys from rats treated with a toxic dose of cisplatin or P.HCl alone. Treatment with a saline solution was used as control. Dehydrogenase activities [succinate dehydrogenase (SDH) and NADPH diaphorase reaction demonstrating nitric oxide synthase (NOS/NADPHd)] and phosphatase activities [K+ p-nitrophenyl phosphatase (K+ pNPPase), alkaline phosphatase (AlPase) and acid phosphatase (AcPase)] were studied on cryostatic sections of kidneys from controls and treated rats. Evidence of heavy morphological damage and altered AlPase and AcPase activities induced by cisplatin were observed in the S3 segment of the proximal tubules. In addition, SDH and K+ pNPPase activities showed some changes in the distal tubule cells. The NOS/NADPHd activity in macula densa was drastically reduced. Combined treatment of cisplatin and P.HCl greatly attenuated morphological alterations of the rat kidney and reduced the changes in enzyme activities, except for NOS/NADPHd activity, compared to the cisplatin-treated group of animals. The study indicates that, in cisplatin-induced nephrotoxicity, a significant role is played by enzyme activities, in particular K+ pNPPase and NOS/NADPHd, and that P.HCl can mitigate the nephrotoxicity of cisplatin, possibly by influencing some enzyme activities involved in important renal metabolic pathways.",
keywords = "Cisplatin, Enzymes, Nephrotoxicity, Procaine",
author = "Carla Fenoglio and Boicelli, {Clodomiro Andrea} and Massimo Ottone and Concetta Addario and Patrizia Chiari and Maurizio Viale",
year = "2002",
month = "11",
doi = "10.1097/00001813-200211000-00008",
language = "English",
volume = "13",
pages = "1043--1054",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Protective effect of procaine hydrochloride on cisplatin-induced alterations in rat kidney

AU - Fenoglio, Carla

AU - Boicelli, Clodomiro Andrea

AU - Ottone, Massimo

AU - Addario, Concetta

AU - Chiari, Patrizia

AU - Viale, Maurizio

PY - 2002/11

Y1 - 2002/11

N2 - Efforts have been made to reduce the undesirable side effects of cisplatin, mainly nephro- and neurotoxicity, but their reduction is usually accompanied by a concomitant inhibition of antitumor activity. The local anesthetic procaine hydrochloride (P.HCl) improves the therapeutic index of cisplatin not only by the reduction of its nephro- and hemotoxicity, but also by an increase of its antitumor activity. We therefore investigated the effects of a combined treatment of cisplatin and P.HCl on rat kidneys and compared this to kidneys from rats treated with a toxic dose of cisplatin or P.HCl alone. Treatment with a saline solution was used as control. Dehydrogenase activities [succinate dehydrogenase (SDH) and NADPH diaphorase reaction demonstrating nitric oxide synthase (NOS/NADPHd)] and phosphatase activities [K+ p-nitrophenyl phosphatase (K+ pNPPase), alkaline phosphatase (AlPase) and acid phosphatase (AcPase)] were studied on cryostatic sections of kidneys from controls and treated rats. Evidence of heavy morphological damage and altered AlPase and AcPase activities induced by cisplatin were observed in the S3 segment of the proximal tubules. In addition, SDH and K+ pNPPase activities showed some changes in the distal tubule cells. The NOS/NADPHd activity in macula densa was drastically reduced. Combined treatment of cisplatin and P.HCl greatly attenuated morphological alterations of the rat kidney and reduced the changes in enzyme activities, except for NOS/NADPHd activity, compared to the cisplatin-treated group of animals. The study indicates that, in cisplatin-induced nephrotoxicity, a significant role is played by enzyme activities, in particular K+ pNPPase and NOS/NADPHd, and that P.HCl can mitigate the nephrotoxicity of cisplatin, possibly by influencing some enzyme activities involved in important renal metabolic pathways.

AB - Efforts have been made to reduce the undesirable side effects of cisplatin, mainly nephro- and neurotoxicity, but their reduction is usually accompanied by a concomitant inhibition of antitumor activity. The local anesthetic procaine hydrochloride (P.HCl) improves the therapeutic index of cisplatin not only by the reduction of its nephro- and hemotoxicity, but also by an increase of its antitumor activity. We therefore investigated the effects of a combined treatment of cisplatin and P.HCl on rat kidneys and compared this to kidneys from rats treated with a toxic dose of cisplatin or P.HCl alone. Treatment with a saline solution was used as control. Dehydrogenase activities [succinate dehydrogenase (SDH) and NADPH diaphorase reaction demonstrating nitric oxide synthase (NOS/NADPHd)] and phosphatase activities [K+ p-nitrophenyl phosphatase (K+ pNPPase), alkaline phosphatase (AlPase) and acid phosphatase (AcPase)] were studied on cryostatic sections of kidneys from controls and treated rats. Evidence of heavy morphological damage and altered AlPase and AcPase activities induced by cisplatin were observed in the S3 segment of the proximal tubules. In addition, SDH and K+ pNPPase activities showed some changes in the distal tubule cells. The NOS/NADPHd activity in macula densa was drastically reduced. Combined treatment of cisplatin and P.HCl greatly attenuated morphological alterations of the rat kidney and reduced the changes in enzyme activities, except for NOS/NADPHd activity, compared to the cisplatin-treated group of animals. The study indicates that, in cisplatin-induced nephrotoxicity, a significant role is played by enzyme activities, in particular K+ pNPPase and NOS/NADPHd, and that P.HCl can mitigate the nephrotoxicity of cisplatin, possibly by influencing some enzyme activities involved in important renal metabolic pathways.

KW - Cisplatin

KW - Enzymes

KW - Nephrotoxicity

KW - Procaine

UR - http://www.scopus.com/inward/record.url?scp=12244271446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12244271446&partnerID=8YFLogxK

U2 - 10.1097/00001813-200211000-00008

DO - 10.1097/00001813-200211000-00008

M3 - Article

VL - 13

SP - 1043

EP - 1054

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 10

ER -